project id: TCGA-PRAD; case submitter id: TCGA-J9-A8CP; source center: 23; state: released; a260 a280 ratio: 1.87; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.79; rna integrity number: 8.6; age at index: 66; days to birth: -24299; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 24299; ajcc clinical m: M0; ajcc clinical t: T2a; ajcc pathologic t: T3a; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 386.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 3; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 113; initial weight: 90.0; sample id: 5bd08756-9dfd-4b50-ba8a-a389bd863a39; sample submitter id: TCGA-J9-A8CP-01A; portion id: cf2f7e9f-041a-467a-b6fe-0e9aa4989139; portion submitter id: TCGA-J9-A8CP-01A-11; slide id: ce9762cd-8950-45f9-8d87-d7a40515e200; slide submitter id: TCGA-J9-A8CP-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 2.0; percent stromal cells: 38.0; percent tumor cells: 60.0; percent tumor nuclei: 70.0; section location: TOP;